Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
Feb '17
|
Lord Arbuthnot of Edrom
|
|
Neuro-bio / NMS:NBIX |
£43.24
|
£142.73
|
230.09%
|
£231,061.50
|
Apr '16
|
Baroness Greenfield
|
|
Neuro-bio / NMS:NBIX |
£46.13
|
£142.73
|
209.41%
|
£216,585.72
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Journey Medical / NCM:DERM |
£3.74
|
£7.05
|
88.50%
|
£131,951.88
|
Jul '23
|
Lord Sassoon
|
|
Haleon / LSE:HLN.L |
£336.10
|
£341.90
|
1.73%
|
£71,207.97
|
Mar '25
|
Lord Fink
|
|
Zoetis / NYQ:ZTS |
£162.82
|
£146.93
|
-9.76%
|
£63,168.52
|
Apr '21
|
Baroness Deech
|
|
Zoetis / NYQ:ZTS |
£168.10
|
£146.93
|
-12.59%
|
£61,184.41
|
Mar '17
|
Lord Lloyd-Webber
|
|
Hikma Pharmaceuticals / LSE:HIK.L |
£2,026.00
|
£1,627.00
|
-19.69%
|
£56,214.22
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Evotec / NMS:EVO |
£7.13
|
£3.64
|
-48.95%
|
£35,736.33
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.